These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 6406615)

  • 1. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans.
    Pollack M
    J Infect Dis; 1983 Jun; 147(6):1090-8. PubMed ID: 6406615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent experience with Pseudomonas aeruginosa immune globulin for the treatment of experimental pneumonia.
    Pennington JE
    J Hosp Infect; 1988 Aug; 12 Suppl D():55-60. PubMed ID: 2902130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa.
    Collins MS; Roby RE
    Am J Med; 1984 Mar; 76(3A):168-74. PubMed ID: 6424446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species.
    Cryz SJ; Fürer E; Sadoff JC; Fredeking T; Que JU; Cross AS
    J Infect Dis; 1991 May; 163(5):1055-61. PubMed ID: 1902245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia.
    Pennington JE; Pier GB; Sadoff JC; Small GJ
    Rev Infect Dis; 1986; 8 Suppl 4():S426-33. PubMed ID: 2944209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
    Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
    Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia.
    Pennington JE; Small GJ; Lostrom ME; Pier GB
    Infect Immun; 1986 Oct; 54(1):239-44. PubMed ID: 3093385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of passive immunotherapy in the treatment of experimental Pseudomonas aeruginosa infections in burns.
    Neely AN; Holder IA
    Antibiot Chemother (1971); 1987; 39():26-40. PubMed ID: 3118788
    [No Abstract]   [Full Text] [Related]  

  • 9. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
    Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
    Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Pseudomonas aeruginosa activity of an intravenous human IgG preparation in burned mice.
    Collins MS; Roby RE
    J Trauma; 1983 Jun; 23(6):530-4. PubMed ID: 6408266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-flagellin IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound murine models in a non-type-specific mode.
    Ahmadi TS; Mousavi Gargari SL; Talei D
    Mol Immunol; 2021 Aug; 136():118-127. PubMed ID: 34130152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.
    Kinoshita M; Kato H; Yasumoto H; Shimizu M; Hamaoka S; Naito Y; Akiyama K; Moriyama K; Sawa T
    Hum Vaccin Immunother; 2016 Nov; 12(11):2833-2846. PubMed ID: 27454613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.
    Hemachandra S; Kamboj K; Copfer J; Pier G; Green LL; Schreiber JR
    Infect Immun; 2001 Apr; 69(4):2223-9. PubMed ID: 11254577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Passive immunotherapy for treatment of endobronchitis in cystic fibrosis].
    Moss RB
    Infusionsther Transfusionsmed; 1993 Apr; 20 Suppl 1():42-6; discussion 47. PubMed ID: 8499750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bivalent flagellin immunotherapy protects mice against Pseudomonas aeruginosa infections in both acute pneumonia and burn wound models.
    Ahmadi H; Behrouz B; Irajian G; Amirmozafari N; Naghavi S
    Biologicals; 2017 Mar; 46():29-37. PubMed ID: 28065582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of molecular biology on Pseudomonas aeruginosa immunization.
    Pennington JE
    J Hosp Infect; 1988 Feb; 11 Suppl A():96-102. PubMed ID: 2896754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A polyvalent human gamma-globulin immune to Pseudomonas aeruginosa: passive protection of mice against lethal infection.
    Fisher MW
    J Infect Dis; 1977 Aug; 136 Suppl():S181-5. PubMed ID: 70492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-PcrV IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound models.
    Ranjbar M; Behrouz B; Norouzi F; Mousavi Gargari SL
    Mol Immunol; 2019 Dec; 116():98-105. PubMed ID: 31634816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of the use of human hyperimmune plasma against Pseudomonas protein for protection against Pseudomonas sepsis in burn mice].
    Xu WS
    Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi; 1993 Jan; 9(1):52-5, 79. PubMed ID: 8330248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical trial of i.v. tetravalent hyperimmune Pseudomonas globulin G in burned patients.
    Hunt JL; Purdue GF
    J Trauma; 1988 Feb; 28(2):146-51. PubMed ID: 3126302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.